Linifanib

Drug Profile

Linifanib

Alternative Names: A-741439; ABT-869; RG-3635

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie
  • Class Antineoplastics; Indazoles; Phenylurea compounds; Small molecules; Urea compounds
  • Mechanism of Action Platelet-derived growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Colorectal cancer; Hepatocellular carcinoma; Non-small cell lung cancer; Renal cancer

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 01 Sep 2012 Abbott terminates phase I trial in Solid tumours in USA (NCT01286974)
  • 24 Aug 2012 Abbott terminates a phase I trial in Solid tumours in US (NCT01506934)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top